Most human influenza strains require lung‑specific

proteases to cleave hemagglutinin (HA). A novel mutation allows HA cleavage by

a broader range of host proteases, increasing infectivity without affecting

transmission efficiency or immune recognition.

Assuming this mutation does not increase host mortality

prior to transmission, what is the most likely long‑term outcome?